Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes. In addition, patients treated with AFREZZA had statistically significant lower rates of hypoglycemia, post-prandial glucose levels when measured at 30, 60, 90 and 120 minutes, and fasting blood glucose levels when compared to subcutaneously injected insulin lispro.

ASweetLife Team

Ten Surprising Things that Affect Blood Sugar Levels As the mother of two children with type 1 diabetes, I’ve learned for certain that carbohydrates raise blood sugar and insulin brings it down. And I've also learned that there…
FDA Rejects Sanofi-Lexicon Oral Medication for Type… The FDA has denied approval of Sanofi and Lexicon's drug, sotagliflozin, as an add-on to insulin therapy in the treatment of Type 1 diabetes. This decision comes just a few…
Hiking the Appalachian Trail with Type 1 Diabetes,… We found Mike Joyce in the famous TypeOneGrit Facebook group, where he was advising on the best ways to stay low carb on long wilderness trips. When Mike switched to…
Country Music Star Eric Paslay Levels With Us about… Diagnosed at age 10 with Type 1 diabetes, Eric Paslay grew up wanting to help kids with the same condition. Somewhere along the way he became a country music star…
Trump To Slash Insulin Costs for Medicare Patients President Trump has announced that monthly co-pays for Medicare insulin will be capped at just $35, beginning in January 2021. "This is a big day for seniors," President Trump said…